Nippon Shinyaku Co., Ltd.
4516JapanPharmaceutical
Nippon Shinyaku Co., Ltd. (4516) reported JPY 166.1bn of revenue in the financial year ended 2026-03-31.
Reported financials
Figures are as filed, in billions of yen (JPY bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported. Statements are on a standalone basis.
| Financial year ended | 2026-03-31 |
|---|---|
| Revenue | 166.1 |
| Operating profit | 34.2 |
| Net profit | 33 |
| Total assets | 303.2 |
| Equity | 261.3 |
Ratios from those figures
Each ratio is computed from the two lines above it. A dash means an input was missing or the denominator was zero — not that the value is zero.
| Operating margin | 20.6% |
|---|---|
| Net margin | 19.9% |
| Equity / assets | 86.2% |
| Return on equity | 12.6% |
| Asset turnover | 0.55 |
These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.
What the market puts on it
| Market capitalisation | JPY 359.4bn |
|---|---|
| Share price | JPY 5,115.6 |
| Shares | 70,251,484 |
| Earnings per share | JPY 441 |
| Book value per share | JPY 3,876.51 |
| Price / earnings | 11.6 |
| Price / book | — |
We could not compute price to book here. Reason recorded at collection: BPS basis (consolidated or parent-only) is not stated in the filing
Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.
Other companies in Pharmaceutical
79 listed companies file under this classification. Showing 12.
- AnGes, Inc.
- ASKA Pharmaceutical Holdings Co., Ltd.
- Astellas Pharma Inc.
- BrightPath Biotherapeutics Co., Ltd
- Carna Biosciences, Inc.
- Chiome Bioscience Inc.
- Chordia Therapeutics Inc.
- CHUGAI PHARMACEUTICAL CO., LTD.
- CHUKYOIYAKUHIN CO.,LTD.
- Cuorips Inc.
- Cyfuse Biomedical K.K.
- D.Western Therapeutics Institute, Inc.